Ziresovir Shows Promise in Alleviating Bronchiolitis Symptoms in Hospitalized Infants with RSV: Study
China: In a promising development for pediatric care, a recent study has highlighted the efficacy of Ziresovir in treating infants hospitalized due to respiratory syncytial virus (RSV) infection. The research, published in the New England Journal of Medicine, provides vital insights into managing bronchiolitis, a common respiratory condition that can lead to severe complications in young children.
The researchers found that treatment with Ziresovir, an antiviral medication, significantly alleviated the signs and symptoms of bronchiolitis in infants and young children hospitalized with RSV infection, with no safety concerns reported.
Respiratory syncytial virus (RSV) is a major cause of serious illness in infants, and currently, there is no effective treatment available. However, results from a phase 2 trial indicate that ziresovir may be an effective option for treating infants hospitalized with RSV infection.
Against the above background, Xin Ni, Beijing Children’s Hospital, Beijing, China, and colleagues conducted a phase 3, multicenter, double-blind, randomized, placebo-controlled trial in China. The researchers enrolled participants aged 1 to 24 months hospitalized with RSV infection. They were randomly assigned in a 2:1 ratio to receive either ziresovir (doses ranging from 10 to 40 mg based on body weight) or a placebo, administered twice daily for five days.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.